Printer Friendly

APPLIED DNA SYSTEMS, INC. REPORTS RESULTS

 APPLIED DNA SYSTEMS, INC. REPORTS RESULTS
 WARWICK, R.I., Nov. 20 /PRNewswire/ -- Applied DNA Systems, Inc.


(NASDAQ: ADNA) reported that net loss per share of common stock for the nine months ended Sept. 30, 1991 decreased to $0.017 from $0.125 for the nine months ended Sept. 30, 1990.
 Net loss for the nine months ended Sept. 30, 1991 decreased to $315,444 from $1,244,389 for the nine months ended Sept. 30, 1990.
 Revenues for the nine months ended Sept. 30, 1991 increased to $735,060 from $319,127 for the nine months ended Sept. 30, 1990. This increase resulted primarily from an increase in the sale of assays and revenues of $102,544 derived from a reduction in accounts payable by certain vendors prior to the equity investment on June 4, 1991, and $100,000 resulting from a terminated agreement with a major pharmaceutical company.
 Assay sales for the nine months ended Sept. 30, 1991, increased to $378,410 from $192,459 for the nine months ended Sept. 30, 1991. This increase resulted primarily from a higher proporation of assays billed, whereas in prior periods assays performed for ongoing clinical trials were not billed.
 The company is a biomedical, development-stage company. Its major scientific product, marketed by its wholly owned subsidiary Analytical Biosystems Corporation (ABC), is a patented laboratory procedure, the Fluorescent Cytoprint Assay (FCA). This assay measures the effectiveness of chemotherapeutic agents in destroying cancer cells.
 -0- 11/20/91
 /CONTACT: Doug MacDougall of Applied DNA Systems, 401-732-6782/
 (ADNA) CO: Applied DNA Systems ST: Rhode Island IN: MTC SU: ERN


PB-SH -- NE010 -- 5412 11/20/91 12:19 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 20, 1991
Words:274
Previous Article:INTERMAGNETICS GENERAL AWARDED PROGRAM TO DESIGN MOTOR FOR MAGLEV VEHICLE
Next Article:FEDERAL HOUSING FINANCE BOARD ISSUES FINAL COMMUNITY SUPPORT REGULATION
Topics:


Related Articles
APPLIED DNA SYSTEMS, INC. REPORTS YEAR-END EARNINGS
APPLIED DNA SYSTEMS REPORTS FINANCIAL RESULTS
Roche Grants PCR License to Perkin-Elmer for DNA-Based Diagnostics
SEQUENOM Systems Used to Determine Origin of Mad Cow Case; Independent Analyses Conducted by Two Genetic Testing Companies for the USDA.
SENSE Holdings, Inc. and Applied DNA Sciences, Inc. Join to Develop and Market Products to Prevent Identity Theft; - In a strategic co-development...
Epoch Biosciences Licenses its Eclipse Dark Quencher to Applied Biosystems.
Applied DNA Sciences, Inc. Demonstrates DNA-Embedded Security Solutions at the 49th Annual ASIS International Seminar & Exhibits at Booth #4441; -...
Applied DNA Sciences Signs VAR Agreement With Sequiam Corporation; - Company Will Start to Incorporate Applied DNA Sciences' Patented DNA- Embedded...
Epoch Biosciences Expands License Agreement With Celera Diagnostics.
Applied DNA Sciences Launches DNA Encryption and Authentication Project in Collaboration with Stony Brook University.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters